Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.50 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | GLP1R | P43220 | 7/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24435855 | 1.00 | FAAH (0.54) | FAAHDNM1LPAR1LPAR2CASP2 | |
| SCHEMBL24435860 | 1.00 | FAAH (0.54) | FAAHDNM1LPAR1LPAR2CASP2 | |
| SCHEMBL24435906 | 1.00 | FAAH (0.54) | FAAHDNM1LPAR1LPAR2CASP2 | |
| SCHEMBL24435907 | 1.00 | FAAH (0.54) | FAAHDNM1LPAR1LPAR2CASP2 | |
| SCHEMBL16273323 | 0.94 | FAAH (0.45) | FAAHDNM1LPAR1LPAR2CASP2 | |
| SCHEMBL24484089 | 0.94 | FAAH (0.45) | FAAHDNM1LPAR1LPAR2CASP2 | |
| SCHEMBL22198369 | 0.94 | TSHR (0.46) | FAAHDNM1LPAR1LPAR2ENPP2 | |
| SCHEMBL22221692 | 0.92 | CASP2 (0.53) | FAAHDNM1CASP2GLP1RNAAA | |
| SCHEMBL25067300 | 0.92 | FAAH (0.59) | FAAHDNM1LPAR1LPAR2CASP2 | |
| SCHEMBL7650140 | 0.92 | FAAH (0.62) | FAAHDNM1LPAR1LPAR2CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20220152210-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152210-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | PCSK9, LDLR, PCSK7 | FAAH 4258/4885DNM1 930/4885LPAR1 126/4885 |
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | PCSK9, LDLR, PCSK7 | FAAH 4258/4885DNM1 930/4885LPAR1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.